These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17554232)

  • 1. [Niacin in therapy].
    Nagalski A; Bryła J
    Postepy Hig Med Dosw (Online); 2007 May; 61():288-302. PubMed ID: 17554232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
    Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
    J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nicotinic acid: an unjustly neglected remedy].
    Zák A; Zeman M; Vecka M; Tvrzická E
    Cas Lek Cesk; 2006; 145(11):825-31. PubMed ID: 17168412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
    Pike NB
    J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin stimulates adiponectin secretion through the GPR109A receptor.
    Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
    Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
    Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
    Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
    Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipokines and treatment with niacin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Metabolism; 2006 Oct; 55(10):1283-5. PubMed ID: 16979396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinic acid in the treatment of hyperlipidaemia.
    Drexel H
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future of GPR109A agonists in the treatment of dyslipidaemia.
    Wanders D; Judd RL
    Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Important considerations for treatment with dietary supplement versus prescription niacin products.
    Backes JM; Padley RJ; Moriarty PM
    Postgrad Med; 2011 Mar; 123(2):70-83. PubMed ID: 21474895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.